Research ExplorerPublicationsBioprosthetic valve fracture: Predictors of outcome and foll...

Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study

Standard

Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study. / Brinkmann, Christina; Abdel-Wahab, Mohamed; Bedogni, Francesco; Bhadra, Oliver D; Charbonnier, Gaetan; Conradi, Lenard; Hildick-Smith, David; Kargoli, Faraj; Latib, Azeem; Van Mieghem, Nicolas M; Miura, Mizuki; Mylotte, Darren; Landes, Uri; Pilgrim, Thomas; Riess, Friedrich-Christian; Taramasso, Maurizio; Tchétché, Didier; Testa, Luca; Thiele, Holger; Webb, John; Windecker, Stephan; Witt, Julian; Wohlmuth, Peter; Wolf, Alexander; Schofer, Joachim.

In: CATHETER CARDIO INTE, Vol. 98, No. 4, 10.2021, p. 756-764.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brinkmann, C, Abdel-Wahab, M, Bedogni, F, Bhadra, OD, Charbonnier, G, Conradi, L, Hildick-Smith, D, Kargoli, F, Latib, A, Van Mieghem, NM, Miura, M, Mylotte, D, Landes, U, Pilgrim, T, Riess, F-C, Taramasso, M, Tchétché, D, Testa, L, Thiele, H, Webb, J, Windecker, S, Witt, J, Wohlmuth, P, Wolf, A & Schofer, J 2021, 'Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study', CATHETER CARDIO INTE, vol. 98, no. 4, pp. 756-764. https://doi.org/10.1002/ccd.29755

APA

Brinkmann, C., Abdel-Wahab, M., Bedogni, F., Bhadra, O. D., Charbonnier, G., Conradi, L., Hildick-Smith, D., Kargoli, F., Latib, A., Van Mieghem, N. M., Miura, M., Mylotte, D., Landes, U., Pilgrim, T., Riess, F-C., Taramasso, M., Tchétché, D., Testa, L., Thiele, H., ... Schofer, J. (2021). Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study. CATHETER CARDIO INTE, 98(4), 756-764. https://doi.org/10.1002/ccd.29755

Vancouver

Brinkmann C, Abdel-Wahab M, Bedogni F, Bhadra OD, Charbonnier G, Conradi L et al. Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study. CATHETER CARDIO INTE. 2021 Oct;98(4):756-764. https://doi.org/10.1002/ccd.29755

Bibtex

@article{c314a28686d84e948e6318bcd233a994,
title = "Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study",
abstract = "OBJECTIVES: To evaluate outcome and its predictors of bioprosthetic valve fracture (BVF) in patients undergoing valve-in-valve transcatheter aortic valve replacement (VIV-TAVR).BACKGROUND: BVF is feasible and reduces transvalvular gradients in VIV-TAVR-procedures, but follow-up-data and information on factors influencing the outcome are missing.METHODS: The 81 cases of BVF-VIV-TAVR were collected from 14 international centers.RESULTS: Predominantly transcatheter heart valve (THV) was implanted first, followed by BVF. VARC-2 defined device success was 93%, most failures were attributed to residual high gradients. Mean gradients decreased from 37 ± 13 mmHg to 10.8 ± 5.9 mmHg (p < 0.001). BVF reduced the gradient by 16 mmHg. During follow-up (FU, 281 ± 164 days) mean gradient remained stable (10.8 ± 5.9 mmHg at discharge, 12.4 ± 6.3 mmHg at FU, p = ns). In-hospital major adverse events occurred in 3.7%. Event-free survival at 276 ± 237.6 days was 95.4%. The linear mixed model identified balloon-expandable valves (BEV), Mitroflow surgical valve, stenotic surgical bioprostheses and balloon only 1 mm larger than the true internal diameter of the surgical valve as predictors for higher gradients.CONCLUSIONS: BVF is safe and can significantly reduce gradients, which remain stable at FU. BEV, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm are predictors for higher final gradients.",
keywords = "Aortic Valve/diagnostic imaging, Aortic Valve Stenosis/diagnostic imaging, Bioprosthesis, Follow-Up Studies, Heart Valve Prosthesis, Hemodynamics, Humans, Prosthesis Design, Prosthesis Failure, Transcatheter Aortic Valve Replacement/adverse effects, Treatment Outcome",
author = "Christina Brinkmann and Mohamed Abdel-Wahab and Francesco Bedogni and Bhadra, {Oliver D} and Gaetan Charbonnier and Lenard Conradi and David Hildick-Smith and Faraj Kargoli and Azeem Latib and {Van Mieghem}, {Nicolas M} and Mizuki Miura and Darren Mylotte and Uri Landes and Thomas Pilgrim and Friedrich-Christian Riess and Maurizio Taramasso and Didier Tch{\'e}tch{\'e} and Luca Testa and Holger Thiele and John Webb and Stephan Windecker and Julian Witt and Peter Wohlmuth and Alexander Wolf and Joachim Schofer",
note = "{\textcopyright} 2021 Wiley Periodicals LLC.",
year = "2021",
month = oct,
doi = "10.1002/ccd.29755",
language = "English",
volume = "98",
pages = "756--764",
journal = "CATHETER CARDIO INTE",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Bioprosthetic valve fracture: Predictors of outcome and follow-up. Results from a multicenter study

AU - Brinkmann, Christina

AU - Abdel-Wahab, Mohamed

AU - Bedogni, Francesco

AU - Bhadra, Oliver D

AU - Charbonnier, Gaetan

AU - Conradi, Lenard

AU - Hildick-Smith, David

AU - Kargoli, Faraj

AU - Latib, Azeem

AU - Van Mieghem, Nicolas M

AU - Miura, Mizuki

AU - Mylotte, Darren

AU - Landes, Uri

AU - Pilgrim, Thomas

AU - Riess, Friedrich-Christian

AU - Taramasso, Maurizio

AU - Tchétché, Didier

AU - Testa, Luca

AU - Thiele, Holger

AU - Webb, John

AU - Windecker, Stephan

AU - Witt, Julian

AU - Wohlmuth, Peter

AU - Wolf, Alexander

AU - Schofer, Joachim

N1 - © 2021 Wiley Periodicals LLC.

PY - 2021/10

Y1 - 2021/10

N2 - OBJECTIVES: To evaluate outcome and its predictors of bioprosthetic valve fracture (BVF) in patients undergoing valve-in-valve transcatheter aortic valve replacement (VIV-TAVR).BACKGROUND: BVF is feasible and reduces transvalvular gradients in VIV-TAVR-procedures, but follow-up-data and information on factors influencing the outcome are missing.METHODS: The 81 cases of BVF-VIV-TAVR were collected from 14 international centers.RESULTS: Predominantly transcatheter heart valve (THV) was implanted first, followed by BVF. VARC-2 defined device success was 93%, most failures were attributed to residual high gradients. Mean gradients decreased from 37 ± 13 mmHg to 10.8 ± 5.9 mmHg (p < 0.001). BVF reduced the gradient by 16 mmHg. During follow-up (FU, 281 ± 164 days) mean gradient remained stable (10.8 ± 5.9 mmHg at discharge, 12.4 ± 6.3 mmHg at FU, p = ns). In-hospital major adverse events occurred in 3.7%. Event-free survival at 276 ± 237.6 days was 95.4%. The linear mixed model identified balloon-expandable valves (BEV), Mitroflow surgical valve, stenotic surgical bioprostheses and balloon only 1 mm larger than the true internal diameter of the surgical valve as predictors for higher gradients.CONCLUSIONS: BVF is safe and can significantly reduce gradients, which remain stable at FU. BEV, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm are predictors for higher final gradients.

AB - OBJECTIVES: To evaluate outcome and its predictors of bioprosthetic valve fracture (BVF) in patients undergoing valve-in-valve transcatheter aortic valve replacement (VIV-TAVR).BACKGROUND: BVF is feasible and reduces transvalvular gradients in VIV-TAVR-procedures, but follow-up-data and information on factors influencing the outcome are missing.METHODS: The 81 cases of BVF-VIV-TAVR were collected from 14 international centers.RESULTS: Predominantly transcatheter heart valve (THV) was implanted first, followed by BVF. VARC-2 defined device success was 93%, most failures were attributed to residual high gradients. Mean gradients decreased from 37 ± 13 mmHg to 10.8 ± 5.9 mmHg (p < 0.001). BVF reduced the gradient by 16 mmHg. During follow-up (FU, 281 ± 164 days) mean gradient remained stable (10.8 ± 5.9 mmHg at discharge, 12.4 ± 6.3 mmHg at FU, p = ns). In-hospital major adverse events occurred in 3.7%. Event-free survival at 276 ± 237.6 days was 95.4%. The linear mixed model identified balloon-expandable valves (BEV), Mitroflow surgical valve, stenotic surgical bioprostheses and balloon only 1 mm larger than the true internal diameter of the surgical valve as predictors for higher gradients.CONCLUSIONS: BVF is safe and can significantly reduce gradients, which remain stable at FU. BEV, Mitroflow surgical valve, stenotic bioprostheses and balloon larger than the true internal diameter of the surgical valve of only 1 mm are predictors for higher final gradients.

KW - Aortic Valve/diagnostic imaging

KW - Aortic Valve Stenosis/diagnostic imaging

KW - Bioprosthesis

KW - Follow-Up Studies

KW - Heart Valve Prosthesis

KW - Hemodynamics

KW - Humans

KW - Prosthesis Design

KW - Prosthesis Failure

KW - Transcatheter Aortic Valve Replacement/adverse effects

KW - Treatment Outcome

U2 - 10.1002/ccd.29755

DO - 10.1002/ccd.29755

M3 - SCORING: Journal article

C2 - 33991385

VL - 98

SP - 756

EP - 764

JO - CATHETER CARDIO INTE

JF - CATHETER CARDIO INTE

SN - 1522-1946

IS - 4

ER -